Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Company Profiles

Set Alert for Emerging Company Profiles

UK Biotech Monument Uses Repurposed Drugs To Target CNS Conditions

Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.   

Neurology Research & Development

Investors Back Microbial Specialist EnteroBiotix’s Series A Financing

Emerging Company Profile: Scotland-based EnteroBiotix will use proceeds from a successful series A financing to advance its nascent pipeline of novel high-diversity microbial therapeutics, enhancing the gut microbiome and eventually targeting multiple indications.

Financing Commercial

France’s PEP-Therapy Cell-Penetrating Peptides To Teach Cancer Cells How ‘To Die Again’

Emerging Company Profile: Armed with fresh funds, French spin-out PEP-Therapy will begin a clinical proof of concept study assessing its lead therapeutic peptide as a potential treatment for metastatic triple-negative breast cancer and platinum-resistant ovarian cancer.

Companies Clinical Trials

Hemab Launches With ‘Pipeline In An Asset’ Approach To Rare Blood Disorders

Emerging Company Profile: Backed by investors including Novo Holdings, HealthCap and RA Capital Management, Hemab Therapeutics is bringing together strong technology and deep expertise to ‘leapfrog’ treatment for several rare bleeding and thrombosis disorders into the 21st century.

Emerging Company Profile Financing

AlzeCure Hunts For Small Molecules In Its Alzheimer’s Quest

Emerging Company Profile: Swedish biotech AlzeCure is developing a portfolio of small-molecule drug candidates for diseases affecting the central nervous system, including Alzheimer’s disease and pain.

Clinical Trials Companies

Danish Start-Up ADCendo Takes Aim At Novel Cancer Target With Fresh Funds

Emerging Company Profile: Denmark-based start-up ADCendo says it now has enough money to begin developing antibody-drug conjugates aimed at the novel cancer target uPARAP/Endo180 and deliver proof of concept in humans for one or more indications by the end of 2025.

Emerging Company Profile Clinical Trials

Leyden Labs Targets Viral Families To Head Off Next Pandemic

Emerging Company Profile: While vaccines target specific viruses, Dutch start-up Leyden Labs is hunting down commonalities in viral families and working on the delivery of intranasal molecules that can protect humans from both known and future viruses.

Emerging Company Profile StartUps and SMEs

STORM’s METTL3 Inhibitor Effective Against AML

Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML.

Emerging Company Profile Commercial

Aelix Therapeutics' Multi-Vector Therapeutic HIV Vaccine Could Be Backbone Of Combination Strategy

Emerging Company Profile: Aelix Therapeutics has constructed a potential therapeutic HIV vaccine to refocus the immune system onto vulnerable parts of the virus, and may allow patients to control viral replication without antiretroviral therapy.

Emerging Company Profile Infectious Diseases

Pneumagen Targeting The Human Glycome To Block Viral Entry

Emerging Company Profile: UK biotech Pneumagen expects to enter clinical studies in 2021 with a potential first-in-class glycan-targeted protein for preventing respiratory tract infections.

Emerging Company Profile Infectious Diseases

Candel Aims High In Next Stage Of Cancer Immunotherapy Mission

Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023.

Emerging Company Profile Companies

Ocugen Eyes Broad Retinitis Pigmentosa Indication With One Gene Therapy

Emerging Company Profile: Turning to gene therapy after its dry eye drug didn’t work out, Ocugen hopes to overcome financial challenges to bring a gene therapy into the clinic for numerous mutations of RP.

StartUps and SMEs Gene Therapy
See All
UsernamePublicRestriction

Register